Actin-related protein 3 Antibodies

Actin-related protein 3 (ACTR3)

ATP-binding component of the Arp2/3 complex, a multiprotein complex that mediates actin polymerization upon stimulation by nucleation-promoting factor (NPF) (PubMed:9000076). The Arp2/3 complex mediates the formation of branched actin networks in the cytoplasm, providing the force for cell motility (PubMed:9000076).

Seems to contact the pointed end of their daughter actin filament (PubMed:9000076). Besides its role in the cytoplasmic cytoskeleton, the Arp2/3 complex also promotes actin polymerization in the nucleus, thereby regulating gene transcription and repair of damaged DNA (PubMed:17220302, PubMed:29925947).

Gene Information

Human
Gene Name:	ACTR3
Uniprot:	P61158
Entrez:	10096

Family

Belongs to:
actin family

Alternative Names

actin-related protein 3; ARP3 (actin-related protein 3, yeast) homolog; ARP3 actin-related protein 3 homolog (yeast); ARP3Actin-like protein 3

Molecular Weight

Mass (kDA):
47.371 kDA

Genomic Context

Human
Location:	2q14.1
Sequence:	2; NC_000002.12 (113889934..113962596)

Subcellular Localizations

Cytoplasm, cytoskeleton. Cell projection. Nucleus. In pre-apoptotic cells, colocalizes with MEFV in large specks (pyroptosomes) (PubMed:19109554).

Diseases

• Wiskott-aldrich Syndrome
• Tissue Adhesions
• Protrusion
• Shigella Infections
• Spinocerebellar Ataxia, Autosomal Recessive 1
• Vaccinia
• Malignant Neoplasms
• Cell Invasion
• Neoplasm Metastasis
• Immunologic Deficiency Syndromes
• Dysplasia
• Nervousness

• Yersinia Infections
• Neoplasms
• Disease Caused By Shigella Flexneri
• Adenocarcinoma
• Tumor Progression
• Bulla
• Infective Disorder

Interacting Proteins

• JUND

Pathways

• Actin Nucleation
• Localization
• Cell Motility
• Endocytosis
• Locomotion
• Cell Migration
• Transport
• Phagocytosis
• Clathrin-mediated Endocytosis
• Receptor-mediated Endocytosis
• Chemotaxis
• Arp2/3 Complex-mediated Actin Nucleation
• Hemostasis

• Actin Filament Network Formation
• Tissue Remodeling
• Cell Growth
• Rna Interference
• Secretion
• Cell Adhesion
• Platelet Activation

PTMs

• Phosphorylation
• Dephosphorylation
• Prenylation

• Cleavage
• Methylation
• Ribosylation

• Ubiquitination

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/ACTR3

Best Uses Of The ACTR3 Marker

This article focuses upon the benefits of Anti-Actin-related protein 3(ACTR3) Marker as well as its clinical applications. Boster Bio ACTR3 is available in IHC or WB formats. The antibody reacts well with samples from Rat, Mouse, and Human. Here are some frequently asked questions about ACTR3 antibodies.

Anti-Actin-related protein 3 ACTR3 Marker

The Anti-Actin related protein 3 ANTR3Marker has been validated against many cancer-related genes. The predicted regulation of 249 genes by the miR-181a-3phsa transcript was found. Some of the targets include ADAMTS18 (CDh23), PDIA6, IPO8, IGF2BP2, SSX2IP and HOXA9.

Boster Bio's Anti-Actin-related Protein 3 ANTR3 marker is an IHC/WB assay marker. It reacts with Rat, Mouse, and Human. The antibody was tested against 82 different cancer genes. This antibody targets ACTR3, BCL11A and ATM in addition to FBXO11.

Clinical Applications

The challenges of translating statistical concepts into clinical practice are highlighted by the development of a new marker to detect pulmonary embolism. The new marker identifies patients with a good prognosis and allows them to forego adjuvant chemotherapy, sparing them from the side effects. Currently, the ACTR3 hormone-sensitive marker is the only one for breast cancer. However, this marker is not a reliable biomarker for every malignancy.

The difficulty in translating genetic risk factors to clinical practice is that they are not intuitively understandable. Both patients and doctors may perceive them as normal, or pathological, which could lead to ethical issues. Before making any medical decisions, it's important to understand the role of genetics in medicine. This study highlights the challenges and calls for further research into this genetic marker. This study highlights the need for additional research to validate these findings and provide a solid base for making decisions.

There are many clinical uses of the ACTR3 marker. But the fundamental question is how to use it. What ethical issues can be raised by the use of genetic predictive marker? In France, bioethics law, as well as European bioethics, frame the production and use of genetic information. HLA/B*27 studies, for instance, highlight the challenges and stakes involved.

In the United States, the use of HLA-B*27 is associated with a higher incidence of ankylosing spondylitis. Despite these ethical concerns, HLA-B*27 is not used to diagnose ankylosing. It is now mandatory to test patients with ankylosing spinelitis. This means that doctors must be trained to perform this test on the appropriate patient.